AVTE - Aerovate Therapeutics, Inc.
IEX Last Trade
2.635
0.015 0.569%
Share volume: 166
Last Updated: Thu 26 Dec 2024 04:30:16 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$2.62
0.02
0.57%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
2.77%
1 Month
-2.99%
3 Months
31.98%
6 Months
79.31%
1 Year
-87.57%
2 Year
-90.68%
Key data
Stock price
$2.64
DAY RANGE
$2.60 - $2.62
52 WEEK RANGE
$1.46 - $32.42
52 WEEK CHANGE
-$89.28
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Timothy P. Noyes
Region: US
Website: aerovatetx.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aerovatetx.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aerovate Therapeutics, Inc. focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company is advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Recent news